From this point, inhibiting inflammatory cytokine secretion or IL-17A+IFN-γ+CD4+ T cell differentiation may slow down or limit immune-mediated intestinal damage, which may provide a theoretical basis for IBD immunotherapy in the future. Here, IL17A is linked to inflammatory bowel disease.